MXCT MaxCyte Inc
- Stocks
- Healthcare
- NASDAQ: MXCT
Price (delayed)
$1.67
Market cap
$178.03M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.43
Enterprise value
$181.32M
Relative Growth:
Rel. Growth:
11
Relative Strength:
Rel. Strength:
5
Relative Valuation:
Rel. Valuation:
12
Relative Profitability:
Rel. Profitability:
27
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to
Highlights
The company's gross profit fell by 29% YoY and by 6% QoQ
MXCT's net income is down by 26% YoY and by 7% QoQ
Key stats
What are the main financial stats of MXCT
Market
Valuations
Earnings
Shares outstanding
106.61M
Market cap
$178.03M
Enterprise value
$181.32M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.93
Price to sales (P/S)
4.97
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.07
Revenue
$35.75M
Gross profit
$28.53M
Operating income
-$53.48M
Net income
-$44.77M
EBIT
-$44.77M
EBITDA
-$39.83M
Free cash flow
-$38.27M
Per share
Balance sheet
Liquidity
EPS
-$0.43
EPS diluted
-$0.43
Free cash flow per share
-$0.36
Book value per share
$1.79
Revenue per share
$0.34
TBVPS
$2.02
Total assets
$219.75M
Total liabilities
$29.03M
Debt
$18.51M
Equity
$190.72M
Working capital
$131.66M
Debt to equity
0.1
Current ratio
12.39
Quick ratio
11.45
Net debt/EBITDA
-0.08
Margins
Efficiency
Dividend
EBITDA margin
-111.4%
Gross margin
79.8%
Net margin
-125.2%
Operating margin
-149.6%
Return on assets
-19.1%
Return on equity
-22.1%
Return on invested capital
-21.3%
Return on capital employed
-21.5%
Return on sales
-125.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MXCT stock price
How has the MaxCyte stock price performed over time
Intraday
3.73%
1 week
10.6%
1 month
-2.34%
1 year
-56.74%
YTD
-59.86%
QTD
5.7%
Financial performance
How have MaxCyte's revenue and profit performed over time
Revenue
$35.75M
Gross profit
$28.53M
Operating income
-$53.48M
Net income
-$44.77M
Gross margin
79.8%
Net margin
-125.2%
MXCT's net margin has plunged by 61% YoY and by 13% from the previous quarter
MXCT's operating margin is down by 47% YoY and by 10% QoQ
The company's gross profit fell by 29% YoY and by 6% QoQ
MXCT's net income is down by 26% YoY and by 7% QoQ
Price vs fundamentals
How does MXCT's price correlate with its fundamentals
Growth
What is MaxCyte's growth rate over time
Valuation
What is MaxCyte stock price valuation
P/E
N/A
P/B
0.93
P/S
4.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.07
The EPS has contracted by 26% YoY and by 8% from the previous quarter
MXCT's P/B is 58% below its 5-year quarterly average of 2.2 and 45% below its last 4 quarters average of 1.7
The equity has contracted by 14% YoY and by 4.4% from the previous quarter
MXCT's price to sales (P/S) is 64% less than its 5-year quarterly average of 13.7 and 42% less than its last 4 quarters average of 8.6
The revenue has declined by 21% year-on-year and by 5% since the previous quarter
Efficiency
How efficient is MaxCyte business performance
The ROS has plunged by 61% YoY and by 13% from the previous quarter
The return on equity has declined by 43% year-on-year and by 11% since the previous quarter
The ROA has contracted by 40% YoY and by 11% from the previous quarter
The ROIC has decreased by 36% YoY and by 9% from the previous quarter
Dividends
What is MXCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MXCT.
Financial health
How did MaxCyte financials performed over time
MXCT's quick ratio is down by 13% year-on-year
The current ratio has declined by 13% year-on-year
MXCT's debt is 90% less than its equity
MaxCyte's debt to equity has increased by 25% YoY and by 11% from the previous quarter
The equity has contracted by 14% YoY and by 4.4% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.